Sustained Corticosteroid-Free Clinical Remission During Vedolizumab Maintenance Therapy in Patients with Ulcerative Colitis on Stable Concomitant Corticosteroids During Induction Therapy: A Post Hoc Analysis of GEMINI 1

References

• Torres J, Billioud V, Sachar DB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis as a progressive disease: the forgotten evidence. Inflamm Bowel Dis. 2012;18(7):1356–1363. doi:10.1002/ibd.22839
   PubMed Web of Science ®Google Scholar
• Dart RJ, Samaan MA, Powell N, Irving PM. Vedolizumab: toward a personalized therapy paradigm for people with ulcerative colitis. Clin Exp Gastroenterol. 2017;10:57–66. doi:10.2147/CEG.S110547
   Web of Science ®Google Scholar
• Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009;361(21):2066–2078. doi:10.1056/NEJMra0804647
   PubMed Web of Science ®Google Scholar
• Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142(1):46–54. doi:10.1053/j.gastro.2011.10.001
   PubMed Web of Science ®Google Scholar
• Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017;389(10080):1756–1770. doi:10.1016/S0140-6736(16)32126-2
   PubMed Web of Science ®Google Scholar
• Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2018;390(10114):2769–2778. doi:10.1016/S0140-6736(17)32448-0
   PubMed Web of Science ®Google Scholar
• da Silva BC, Lyra AC, Rocha R, Santana GO. Epidemiology, demographic characteristics and prognostic predictors of ulcerative colitis. World J Gastroenterol. 2014;20(28):9458–9467. doi:10.3748/wjg.v20.i28.9458
   PubMed Web of Science ®Google Scholar
• Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015;12(12):720–727. doi:10.1038/nrgastro.2015.150
   PubMed Web of Science ®Google Scholar
• Williet N, Sarter H, Gower-Rousseau C, et al. Patient-reported outcomes in a French nationwide survey of inflammatory bowel disease patients. J Crohns Colitis. 2017;11(2):165–174. doi:10.1093/ecco-jcc/jjw145
   PubMed Web of Science ®Google Scholar
• Dignass A, Eliakim R, Magro F, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis. 2012;6(10):965–990. doi:10.1016/j.crohns.2012.09.003
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110(9):1324–1338. doi:10.1038/ajg.2015.233
   PubMed Web of Science ®Google Scholar
• Harbord M, Eliakim R, Bettenworth D, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis. 2017;11(7):769–784. doi:10.1093/ecco-jcc/jjx009
   PubMed Web of Science ®Google Scholar
• Kornbluth A, Sachar DB. Practice parameters committee of the American College of Gastroenterology. ulcerative colitis practice guidelines in adults: American College of Gastroenterology, practice parameters committee. Am J Gastroenterol. 2010;105(3):501–523. doi:10.1038/ajg.2009.727
   PubMed Web of Science ®Google Scholar
• Rubin DT, Mody R, Davis KL, Wang CC. Real-world assessment of therapy changes, suboptimal treatment and associated costs in patients with ulcerative colitis or Crohn’s disease. Aliment Pharmacol Ther. 2014;39(10):1143–1155. doi:10.1111/apt.12727
   PubMed Web of Science ®Google Scholar
• Rubin DT, Patel H, Shi S, Mody R. Assessment of corticosteroid-related quality of care measures for ulcerative colitis and Crohn’s disease in the United States: a claims data analysis. Curr Med Res Opin. 2017;33(3):529–536. doi:10.1080/03007995.2016.1267616
   PubMed Web of Science ®Google Scholar
• Waljee AK, Wiitala WL, Govani S, et al. Corticosteroid use and complications in a US inflammatory bowel disease cohort. PLoS One. 2016;11(6):e0158017. doi:10.1371/journal.pone.0158017
   PubMed Web of Science ®Google Scholar
• Cross RK. Safety considerations with the use of corticosteroids and biologic therapies in mild-to-moderate ulcerative colitis. Inflamm Bowel Dis. 2017;23(10):1689–1701. doi:10.1097/MIB.0000000000001261
   Web of Science ®Google Scholar
• Danese S, Fiorino G, Peyrin-Biroulet L, et al. Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. Ann Intern Med. 2014;160(10):704–711. doi:10.7326/M13-2403
   PubMed Web of Science ®Google Scholar
• Lopez A, Ford AC, Colombel JF, Reinisch W, Sandborn WJ, Peyrin-Biroulet L. Efficacy of tumour necrosis factor antagonists on remission, colectomy and hospitalisations in ulcerative colitis: meta-analysis of placebo-controlled trials. Dig Liver Dis. 2015;47(5):356–364. doi:10.1016/j.dld.2015.01.148
   Google Scholar
• Lv R, Qiao W, Wu Z, et al. Tumor necrosis factor alpha blocking agents as treatment for ulcerative colitis intolerant or refractory to conventional medical therapy: a meta-analysis. PLoS One. 2014;9(1):e86692. doi:10.1371/journal.pone.0086692
   PubMed Web of Science ®Google Scholar
• Stidham RW, Lee TC, Higgins PD, et al. Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2014;39(7):660–671. doi:10.1111/apt.12644
   PubMed Web of Science ®Google Scholar
• Allez M, Karmiris K, Louis E, et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohns Colitis. 2010;4(4):355–366. doi:10.1016/j.crohns.2010.04.004
   PubMed Web of Science ®Google Scholar
• Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011;60(6):780–787. doi:10.1136/gut.2010.221127
   PubMed Web of Science ®Google Scholar
• Roda G, Jharap B, Neeraj N, Colombel JF. Loss of response to anti-TNFs: definition, epidemiology, and management. Clin Transl Gastroenterol. 2016;7(1):e135. doi:10.1038/ctg.2015.63
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462–2476. doi:10.1056/NEJMoa050516
   PubMed Web of Science ®Google Scholar
• Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699–710. doi:10.1056/NEJMoa1215734
   PubMed Web of Science ®Google Scholar
• Lewis JD, Chuai S, Nessel L, Lichtenstein GR, Aberra FN, Ellenberg JH. Use of the noninvasive components of the mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis. 2008;14(12):1660–1666. doi:10.1002/ibd.20520
   PubMed Web of Science ®Google Scholar
• Regueiro MD, Greer JB, Hanauer SB. Established management paradigms in IBD: treatment targets and therapeutic tools. Am J Gastroenterol Suppl. 2016;3(3):8–16. doi:10.1038/ajgsup.2016.16
   Google Scholar
• Bressler B, Marshall JK, Bernstein CN, et al. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. Gastroenterology. 2015;148(5):1035–1058 e1033. doi:10.1053/j.gastro.2015.03.001
   PubMed Web of Science ®Google Scholar
• Curtis JR, Westfall AO, Allison J, et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum. 2006;55(3):420–426. doi:10.1002/art.21984
   PubMed Web of Science ®Google Scholar
• Feagan BG, Schreiber S, Wolf DC, et al. Sustained clinical remission with vedolizumab in patients with moderate-to-severe ulcerative colitis. Inflamm Bowel Dis. 2019;25(6):1028–1035. doi:10.1093/ibd/izy323
   PubMed Web of Science ®Google Scholar
• Sands BE, Hanauer SB, Columbel J-F, et al. Reductions in corticosteroid use in patients with ulcerative colitis or crohn’s disease treated with vedolizumab. UEG J. 2013;1(suppl 1):A370.
   Google Scholar
• Loftus EV, Siegel CA, Panaccione R, et al. Corticosteroid dose reduction in ulcerative colitis patients treated with vedolizumab during the GEMINI 1 trial. Am J Gastroenterol. 2015;110(suppl1):S790.Abstract 1859. doi:10.14309/00000434-201510001-01859
   Web of Science ®Google Scholar
• Colombel JF, Rutgeerts P, Reinisch W, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011;141(4):1194–1201. doi:10.1053/j.gastro.2011.06.054
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142(2):257–265. doi:10.1053/j.gastro.2011.10.032
   PubMed Web of Science ®Google Scholar
• Reinisch W, Sandborn WJ, Panaccione R, et al. 52-week efficacy of adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressants. Inflamm Bowel Dis. 2013;19(8):1700–1709. doi:10.1097/MIB.0b013e318281f2b7
   PubMed Web of Science ®Google Scholar